Who is sponsoring NCT01490658?

NCT01490658 is sponsored by Novo Nordisk A/S.

What condition does NCT01490658 study?

NCT01490658 studies Diabetes, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01490658?

Interventions: repaglinide, metformin, repaglinide and metformin combination tablet.

What is the status of NCT01490658?

NCT01490658 is currently COMPLETED.

Last reviewed 2017-02-09 · How we verify

A Randomized, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Volunteers

NCT01490658 Phase 1 COMPLETED

This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	COMPLETED
Enrolment	93
Start date	2006-06
Completion	2006-08

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

repaglinide
metformin
repaglinide and metformin combination tablet

Primary outcomes

Repaglinide and metformin AUC (Area under the Curve) fed state concomitant tablet administration
Repaglinide and metformin AUC (Area under the Curve) NN4440 (2/500) combination tablet
Repaglinide and metformin Cmax (maximum plasma concentration) fed state concomitant tablet administration
NN4440 (2/500) Cmax (maximum plasma concentration) combination tablet

Countries

United States